CenterBook Partners LP Decreases Stock Holdings in MaxCyte, Inc. (NASDAQ:MXCT)

CenterBook Partners LP reduced its position in MaxCyte, Inc. (NASDAQ:MXCT - Free Report) by 17.3% in the 1st quarter, according to the company in its most recent 13F filing with the Securities and Exchange Commission (SEC). The firm owned 717,275 shares of the company's stock after selling 149,734 shares during the period. CenterBook Partners LP owned about 0.67% of MaxCyte worth $1,958,000 as of its most recent filing with the Securities and Exchange Commission (SEC).

Several other large investors have also recently made changes to their positions in the company. Tower Research Capital LLC TRC raised its position in MaxCyte by 123.1% during the fourth quarter. Tower Research Capital LLC TRC now owns 7,564 shares of the company's stock worth $31,000 after acquiring an additional 4,173 shares during the period. BNP Paribas Financial Markets acquired a new position in MaxCyte during the fourth quarter worth $56,000. Kwmg LLC acquired a new position in MaxCyte during the first quarter worth $40,000. Prudential Financial Inc. acquired a new position in MaxCyte during the fourth quarter worth $65,000. Finally, Moors & Cabot Inc. raised its position in MaxCyte by 34.4% during the first quarter. Moors & Cabot Inc. now owns 17,708 shares of the company's stock worth $48,000 after acquiring an additional 4,528 shares during the period. 68.81% of the stock is currently owned by institutional investors and hedge funds.

Wall Street Analysts Forecast Growth

Separately, Wall Street Zen upgraded shares of MaxCyte from a "sell" rating to a "hold" rating in a research report on Sunday, June 8th.

MaxCyte Trading Down 6.0%

Shares of NASDAQ MXCT traded down $0.13 during midday trading on Friday, hitting $2.02. The company's stock had a trading volume of 387,728 shares, compared to its average volume of 615,011. The business's fifty day simple moving average is $2.22 and its two-hundred day simple moving average is $3.08. MaxCyte, Inc. has a 1 year low of $2.00 and a 1 year high of $5.20.

MaxCyte (NASDAQ:MXCT - Get Free Report) last posted its quarterly earnings data on Wednesday, May 7th. The company reported ($0.10) EPS for the quarter, meeting the consensus estimate of ($0.10). MaxCyte had a negative net margin of 110.92% and a negative return on equity of 19.90%. The business had revenue of $10.39 million during the quarter, compared to analyst estimates of $9.05 million. Equities research analysts anticipate that MaxCyte, Inc. will post -0.42 EPS for the current fiscal year.

MaxCyte Company Profile

MaxCyte, Inc, a life sciences company, discovers, develops, and commercializes next-generation cell therapies in the United States and internationally. Its products include ExPERT ATx, a static electroporation instrument for small to medium scale transfection; ExPERT STx, a flow electroporation for protein production and drug development, as well as expression of therapeutic targets for cell-based assays; ExPERT GTx, a flow electroporation for large scale transfection in therapeutic applications; and ExPERT VLx for very large volume cell-engineering.